{"id":"W1986700293","doi":"10.1158/1535-7163.targ-11-c69","title":"Abstract C69: Preliminary activity of temsirolimus, an mTOR inhibitor, in patients with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix: An NCIC-CTG phase II clinical trial.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Temsirolimus; Medicine; Response Evaluation Criteria in Solid Tumors; Internal medicine; Clinical endpoint; Progressive disease; Phases of clinical research; Oncology; Adenosquamous carcinoma; Cancer; Chemotherapy; Cervix; Adenocarcinoma; Surgery; Clinical trial; PI3K/AKT/mTOR pathway; Discovery and development of mTOR inhibitors","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002965335,0.0003151628,0.0007575962,0.0001009861,0.00005721497,0.00000715701,0.0002387803,0.0001139352,0.00009165879],"category_scores_gemma":[0.00002689519,0.0001936991,0.000193962,0.0003761946,0.0002038227,0.0001556602,0.00007076773,0.0003065072,3.54215e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001967189,"about_ca_system_score_gemma":0.000797465,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001048455,"about_ca_topic_score_gemma":0.0009985499,"domain_scores_codex":[0.997641,0.0002624375,0.0007405075,0.0004799438,0.0005474814,0.0003285959],"domain_scores_gemma":[0.9980145,0.00007728383,0.0005626107,0.0009003372,0.0002713321,0.0001739671],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.4129505,0.05280259,0.1760686,0.0004318749,0.001112116,0.0000918775,0.001836571,0.00007582922,0.004759612,0.00002666067,0.00001464114,0.349829],"study_design_scores_gemma":[0.1334081,0.06828085,0.7217058,0.0005672675,0.001173795,0.00000244983,0.0001093106,0.0001834925,0.07396556,0.0000332007,0.0002708627,0.0002992555],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957217,0.001126625,0.00004569632,0.00008205378,0.0003263473,0.0024955,0.000118531,0.00001469718,0.00006882389],"genre_scores_gemma":[0.9986214,0.000280339,0.0004377664,0.0002537568,0.0000503339,0.0002535506,0.00002646614,0.00006028736,0.00001612423],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5456372,"threshold_uncertainty_score":0.7898821,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09987743406618643,"score_gpt":0.3790143645730128,"score_spread":0.2791369305068264,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}